Topical long-term therapy of psoriasis with vitamin D3 analogues, corticosteroids and their two compound formulations: Position paper on evidence and use in daily practice;Topische Langzeittherapie der Psoriasis mit Vitamin-D3-Analoga, Kortikosteroiden und deren Kombinationen: Positionspapier zu Evidenz und praktischer Anwendung

JDDG - Journal of the German Society of Dermatology

Volumn 12, Issue 8, 2014, Pages 667-682

  Augustin, Matthias ^a   Mrowietz, Ulrich ^b   Bonnekoh, Bernd ^c   Rosenbach, Thomas ^d   Thaçi, Diamant ^e   Reusch, Michael ^a   Ardabili, Michael ^d   Reich, Kristian ^d  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c OTTO VON GUERICKE UNIVERSITY   (Germany)

^d Comprehensive Center for Inflammation Medicine Campus Lübeck University of Lübeck ^*  (Germany)

^e UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE; BETAMETHASONE DIPROPIONATE; BETAMETHASONE VALERATE; CALCIPOTRIOL; CALCITRIOL; CLOBETASOL; CLOBETASOL PROPIONATE; COLECALCIFEROL DERIVATIVE; CORTICOSTEROID DERIVATIVE; DESOXIMETASONE; FLUOCINOLONE ACETONIDE; PARATHYROID HORMONE; TACALCITOL; ULOBETASOL PROPIONATE; COLECALCIFEROL; CORTICOSTEROID; DRUG COMBINATION;

BODY SURFACE; BURN; CALCIUM HOMEOSTASIS; CLINICAL PRACTICE; CONCENTRATION RESPONSE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; EVIDENCE BASED MEDICINE; FOLLICULITIS; HUMAN; HYPERCALCEMIA; HYPOTHALAMUS HYPOPHYSIS SYSTEM; LONG TERM CARE; MAINTENANCE THERAPY; MONOTHERAPY; OUTCOME ASSESSMENT; PRURITUS; PSORIASIS; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SCALP PSORIASIS; SKIN ATROPHY; SKIN IRRITATION; SYSTEMATIC REVIEW; TELANGIECTASIA; VITAMIN BLOOD LEVEL; ANALOGS AND DERIVATIVES; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; DRUG COMBINATION; PROTOCOL COMPLIANCE; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; BETAMETHASONE; CALCITRIOL; CHOLECALCIFEROL; CLINICAL TRIALS AS TOPIC; DRUG COMBINATIONS; EVIDENCE-BASED MEDICINE; GUIDELINE ADHERENCE; HUMANS; LONG-TERM CARE; PSORIASIS;

EID: 84905453773     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/ddg.12396     Document Type: Review

References (42)

1. 3-Leitlinie zur Therapie der Psoriasis vulgaris-Update. J Dtsch Dermatol Ges 2012; 10 Suppl 2: S1-S95.
2. Krensel M, Reich K, Bonnekoh B, et al. Characterization of topical treatment for mild psoriasis by dermatologist in Germany [accepted at "Acta Dermatol Venereol " on 24 January, 2014 ].
3. 3-Leitlinie zur Therapie der Psoriasis vulgaris-Methodenreport. J Dtsch Dermatol Ges 2011; 9 (Suppl. 2): e64-e84.
4. Ellis JP, Griffiths WAD, Klaber MR,. Longterm treatment of chronic plaque psoriasis with calcipotriol ointment in patients unresponsive to short contact dithranol. Eur J Clin Res 1995; 7: 247-57.
5. Katz HI, Prawer SE, Medansky RS, et al. Intermittent corticosteroid maintenance treatment of psoriasis: a double-blind multicenter trial of augmented betamethasone dipropionate ointment in a pulse dose treatment regimen. Dermatologica 1991; 183 (4): 269-74.
6. Fleming C, Ganslandt C, Leese GP,. Short- and long-term safety assessment of a two-compound ointment containing calcipotriene/betamethasone dipropionate (Taclonex/Daivobet/Dovobet ointment): hypothalamic-pituitary-adrenal axis function in patients with psoriasis vulgaris. J Drugs Dermatol 2010; 9 (8): 969-74.
7. Kragballe K, Austad J, Barnes L, et al. Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet/Dovobet/Taclonex) in the treatment of psoriasis vulgaris. Dermatology 2006; 213 (4): 319-26.
8. Kragballe K, Austad J, Barnes L, et al. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris. Br J Dermatol 2006; 154 (6): 1155-60.
9. Van de Kerkhof P, Van der Vleuten C, Gerritsen M, et al. Long-term efficacy and safety of once daily treatment of chronic plaque psoriasis with tacalcitol ointment. Eur J Dermatol 1997; 7 (6): 421-5.
10. Lebwohl M, Yoles A, Lombardi K, Lou W,: Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: Effects on the duration of improvement. J Am Acad Dermatol 1998; 39: 447-50.
11. Cullen SI,: Long-term effectiveness and safety of topical calcipotriene for psoriasis. South Med J 1996; 89 (11): 1053-6.
12. Koo J, Blum RR, Lebwohl M,. A randomized, multicenter study of calcipotriene ointment and clobetasol propionate foam in the sequential treatment of localized plaque-type psoriasis: short- and long-term outcomes. J Am Acad Dermatol 2006; 55 (4): 637-41.
13. Miyachi Y, Ohkawara A, Ohkido M, et al. Long-term safety and efficacy of high-concentration (20 μg/g) tacalcitol ointment in psoriasis vulgaris. Eur J Dermatol 2002; 12 (5): 463-8.
14. Lambert J, Trompke C,. Tacalcitol ointment for long-term control of chronic plaque psoriasis in dermatological practice. Dermatology 2002; 204 (4): 321-4.
15. van de Kerkhof PC, Berth-Jones J, Griffiths CE, et al. Long-term efficacy and safety of tacalcitol ointment in patients with chronic plaque psoriasis. Br J Dermatol 2002; 146 (3): 414-22.
16. van de Kerkhof PC, Berth-Jones J, Griffiths CE, et al. Long-term efficacy and safety of tacalcitol ointment in patients with chronic plaque psoriasis. H+G Zeitschrift für Hautkrankheiten 2002; 77 (9): 424-32.
17. Gerritsen MJ, van De Kerkhof PC, Langner A,. Long-term safety of topical calcitriol 3 microg g(-1) ointment. Br J Dermatol 2001; 144 (Suppl 58): 17-9.
18. Langner A, Ashton P, van De Kerkhof PC, Verjans H,. A long-term multicentre assessment of the safety and tolerability of calcitriol ointment in the treatment of chronic plaque psoriasis. Br J Dermatol 1996; 135 (3): 385-9.
19. van de Kerkhof PC, van Harten J, Verjans H,. A long term assessment of the safety and tolerability of calcitriol ointment in the treatment of chronic plaque psoriasis. J Dermatol Treat 1996; 7 (Suppl 1): 11-4.
20. Ramsay CA, Berth-Jones J, Brundin G, et al. Long-term use of topical calcipotriol in chronic plaque psoriasis. Dermatology 1994; 189 (3): 260-4.
21. Poyner T, Hughes JW, Dass BK, Adnitt PI,. Long term treatment of chronic plaque psoriasis with calcipotriol. J Dermatol Treat 1993; 4: 173-7.
22. Kragballe K, Fogh K, Søgaard H,. Long-term efficacy and tolerability of topical calcipotriol in psoriasis. Results of an open study. Acta Derm-Venereol 1991; 71 (6): 475-8.
23. Cornell RC, Stoughton RB,. Six-month controlled study of effect of desoximetasone and betamethasone 17-valerate on the pituitary-adrenal axis. Br J Dermatol 1981; 105 (1): 91-5.
24. Floden CH, Woodbridge P, Samman P, Kurwa AR,. Comparison of the response of psoriasis over a 6-month period, to clobetasol propionate and fluocinolone acetonide ointments. Curr Med Res Opin 1975; 3 (6): 375-81.
25. Corbett MF,. The response of psoriasis to betamethasone valerate and clobetasol propionate. A 6-month controlled study. Br J Dermatol 1976; 94 (Suppl 12): 89-93.
26. Poulin Y, Papp K, Bissonnette R, et al. Clobetasol propionate shampoo 0.05 % is efficacious and safe for long-term control of scalp psoriasis. Cutis 2010; 85 (1): 43-50.
27. Poulin Y, Papp K, Bissonnette R, et al. Clobetasol propionate shampoo 0.05 % is efficacious and safe for long-term control of moderate scalp psoriasis. J Dermatolog Treat 2010; 21 (3): 185-92.
28. Luger TA, Cambazard F, Larsen FG, et al. A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis. Dermatology 2008; 217 (4): 321-8.
29. Barnes L, Altmeyer P, Fôrstrôm L, Stenström MH,. Long-term treatment of psoriasis with calcipotriol scalp solution and cream. Eur J Dermatol 2000; 10 (3): 199-204.
30. Mason AR, Mason J, Cork M, et al. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev 2013; 28 (3): CD005028.
31. Norsgaard H, Gonzalez T, Duenstl G, et al. Beneficial effects of the fixed combination of calcipotriol and betamethasone dipropionate on skin atrophy biomarkers. Poster presented at 21st EADV, 2012: No. PRA12-0845.
32. Augustin M, Peeters P, Radtke M, et al. Cost-effectiveness model of topical treatment of mild to moderate psoriasis vulgaris in Germany. A comparison of calcipotriol/betamethasone (Daivobet/Dovobet/Taclonex) once daily and a morning/evening non-fix combination of calcipotriol and betamethasone. Dermatology 2007; 215 (3): 219-28.
33. Augustin M, Radtke M, van Engen A, et al. Pharmakoökonomisches Modell zur Kosten-Effektivität topischer Behandlungsformen bei leichter bis mittelschwerer Psoriasis vulgaris in Deutschland. J Dtsch Dermatol Ges 2009; 7 (4): 329-38.
34. World Health Organization: Adherence to long term therapy: evidence for action. 2003 http://www.who.int/chp/knowledge/publications/adherence-full- report.pdf (accessed Oct 2011).
35. Augustin M, Holland B, Dartsch D, et al. Adherence in the treatment of psoriasis: a systematic review. Dermatology 2011; 222 (4): 363-74.
36. Carroll CL, Feldman SR, Camacho FT, et al. Better medication adherence results in greater improvement in severity of psoriasis. Br J Dermatol 2004; 151: 895-97.
37. Sticherling M, Eicke C, Anger T,. Praktikabilität der kombinierten Anwendung von Calcipotriol/Betamethason in Gel-Form und Verbesserung der Lebensqualität bei Patienten mit Psoriasis. J Dtsch Dermatol Ges 2013; 11 (5): 420-7.
38. Mrowietz U, Macheleidt O, Eicke C,. Effective treatment and improvement of quality of life in patients with scalp psoriasis by topical use of calcipotriol/betamethasone (Xamiol®-Gel): results form a study in 721 patients. J Dtsch Dermatol Ges 2011; 9 (10): 825-31.
39. Umar N, Schaarschmidt M, Schmieder A, et al. Matching physicians' treatment recommendations to patients' treatment preferences is associated with improvement in treatment satisfaction. J Eur Acad Dermatol Venereol 2013; 27 (6): 763-70.
40. Brown KK, Rehmus WE, Kimball AB,. Determining the relative importance of patient motivations for non-adherence to topical corticosteroid therapy in psoriasis. J Am Acad Dermatol 2006; 55: 607-13.
41. White S, Vender R, Thaçi D, et al. Use of calcipotriene cream (Dovonex cream) following acute treatment of psoriasis vulgaris with the calcipotriene/betamethasone dipropionate two-compound product (Taclonex): a randomized, parallel-group clinical trial. Am J Clin Dermatol 2006: 7 (8): 177-184.
42. Saraceno R, Camplone G, D'Agostino M, et al. Efficacy and maintenance strategies of two-compound formulation calcipotriol and betamethasone dipropionate gel (Xamiol® gel) in the treatment of scalp psoriasis: results from a study in 885 patients. J Dermatolog Treat 2014; 25 (1): 30-3.